Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2013 1
2018 1
2019 1
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Examining advocacy and comprehensive cancer control.
Selig WK, Jenkins KL, Reynolds SL, Benson D, Daven M. Selig WK, et al. Cancer Causes Control. 2005 Oct;16 Suppl 1:61-8. doi: 10.1007/s10552-005-0485-1. Cancer Causes Control. 2005. PMID: 16208575 Review.
Addressing unmet needs for people with cancer cachexia: recommendations from a multistakeholder workshop.
Garcia JM, Dunne RF, Santiago K, Martin L, Birnbaum MJ, Crawford J, Hendifar AE, Kochanczyk M, Moravek C, Piccinin D, Picozzi V, Roeland EJ, Selig WKD, Zimmers TA. Garcia JM, et al. Among authors: selig wkd. J Cachexia Sarcopenia Muscle. 2022 Apr;13(2):1418-1425. doi: 10.1002/jcsm.12910. Epub 2022 Feb 26. J Cachexia Sarcopenia Muscle. 2022. PMID: 35218313 Free PMC article. No abstract available.
Leveraging Patient Preference Information in Medical Device Clinical Trial Design.
Rincon-Gonzalez L, Selig WKD, Hauber B, Reed SD, Tarver ME, Chaudhuri SE, Lo AW, Bruhn-Ding D, Liden B. Rincon-Gonzalez L, et al. Among authors: selig wkd. Ther Innov Regul Sci. 2023 Jan;57(1):152-159. doi: 10.1007/s43441-022-00450-9. Epub 2022 Aug 27. Ther Innov Regul Sci. 2023. PMID: 36030334 Free PMC article.
The promise of Immuno-oncology: implications for defining the value of cancer treatment.
Kaufman HL, Atkins MB, Subedi P, Wu J, Chambers J, Joseph Mattingly T 2nd, Campbell JD, Allen J, Ferris AE, Schilsky RL, Danielson D, Lichtenfeld JL, House L, Selig WKD. Kaufman HL, et al. Among authors: selig wkd. J Immunother Cancer. 2019 May 17;7(1):129. doi: 10.1186/s40425-019-0594-0. J Immunother Cancer. 2019. PMID: 31101066 Free PMC article.
Developing standards for breakthrough therapy designation in oncology.
Horning SJ, Haber DA, Selig WK, Ivy SP, Roberts SA, Allen JD, Sigal EV, Sawyers CL. Horning SJ, et al. Among authors: selig wk. Clin Cancer Res. 2013 Aug 15;19(16):4297-304. doi: 10.1158/1078-0432.CCR-13-0523. Epub 2013 May 29. Clin Cancer Res. 2013. PMID: 23719260 Free PMC article.